Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Definitions  



1.1  Berlin Criteria (2020)  







2 Histology/Progression  





3 Causes/Mechanism  





4 Diagnosis  





5 Treatment  





6 Prognosis  





7 References  














Diffuse alveolar damage






العربية
Català
فارسی
Français
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Diffuse alveolar damage
Micrograph showing hyaline membranes, the key histologic feature of diffuse alveolar damage. H&E stain.
SpecialtyRespirology

Diffuse alveolar damage (DAD) is a histologic term used to describe specific changes that occur to the structure of the lungs during injury or disease. Most often DAD is described in association with the early stages of acute respiratory distress syndrome (ARDS).[1] DAD can be seen in situations other than ARDS (such as acute interstitial pneumonia) and ARDS can occur without DAD.[1]

Definitions[edit]

Berlin Criteria (2020)[edit]

The Berlin Criteria specifies:[4]

  1. Timing: onset of respiratory symptoms within one week of an injury/insult.
  2. Chest Imaging: either chest x-ray or CT scan, must show bilateral opacities that cannot be fully explained by other conditions such as effusion, lung/lobar collapse, or lung nodules.
  3. Origin of Edema: respiratory failure that cannot be fully explained by cardiac failure or fluid overload, this needs objective assessment such as an echocardiogram.
  4. Impaired Oxygenation: this can be determined by looking at the ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2) that can be obtained based on an arterial blood gas test. Note: all PaO2/FiO2 ratios used in the determination of the severity of ARDS require that the patient be on a ventilator at a setting that includes 5 cm H2O or more of positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP).
Level of ARDS PaO2/FiO2 Range PEEP/CPAP
Mild ARDS 201-300 ≥5 cm H2O
Moderate ARDS 101-200
Severe ARDS <100

Histology/Progression[edit]

The epithelial lining of alveoli are composed of two different types of cells. Alveolar type I epithelial cells comprise about 80% of the alveolar surface area and are primarily responsible for gas exchange.[5] Alveolar type II epithelial cells play the critical roles of producing surfactant, moving water out of the airspaces, and regenerating alveolar epithelium.[5] The alveolar type II epithelial cells are more resistant to damage, so after an insult to the alveoli, most of the damage will occur to the alveolar type I epithelial cells.[5]

Left side demonstrate the structure of a normal alveolus including the difference between type I and type II alveolar epithelial cells. Right side depicts what occurs after injury to the alveolus during the acute/exudative phase.

Once the initial insult has damaged the alveoli and begun the process of DAD, the condition will typically progress in three phases: exudative, proliferative, and fibrotic.[6] Below are the description of the phases, paraphrased from Sweeney et al. (2016).[6]

Causes/Mechanism[edit]

DAD can occur in settings other than ARDS and ARDS can occur with histology other than DAD. That being said, the histologic finding of DAD is often associated with the clinical syndrome ARDS but it can also be seen in conditions such as acute interstitial pneumonia (essentially ARDS but without a known inciting cause), acute exacerbation of idiopathic pulmonary fibrosis, and primary graft dysfunction after lung transplant.[1] The most common causes of ARDS are pneumonia, non-pulmonary sepsis, and aspiration.[7]

To reiterate, the hallmark of DAD is hyaline membrane formation.[1] There is a similar process which occurs in newborns called hyaline membrane disease, although the preferred term is surfactant-deficiency disorder, that also has the formation of hyaline membranes.[8] This disorder typically develops due to prematurity, especially when the infant is delivered prior to 36 weeks since surfactant doesn't start being produced until 35 weeks gestation.[8] The lack of surfactant causes alveolar collapse and subsequent damage to the epithelial lining of the alveoli, causing the same path of damage described in the above section.

Diagnosis[edit]

In order to make a diagnosis of DAD a biopsy of the lung must be obtained, processed, and examined microscopically. As described above, the hallmark of diagnosing DAD is the presence of hyaline membranes.[1] Most frequently DAD is associated with ARDS, but since there are clinical criteria (see Berlin criteria above) upon which we can diagnose ARDS, it is often unnecessary in all cases to obtain invasive biopsies of the lung. Additionally, there are limitations of the biopsy test since it is possible to sample a potentially normal area of lung even though there is DAD in the rest of the lung, resulting in a false negative.[1]

Treatment[edit]

The most important factor for treating DAD or ARDS is to treat the underlying cause of the injury to the lungs,[9] for example pneumonia or sepsis. These patients will have problems with oxygenation, meaning they will likely need a breathing tube, medications to keep them comfortable (sedative, paralytic, and/or analgesic), and a mechanical ventilator to breathe for them.[10] The mechanical ventilator will often be set to a setting of at least 5 cm H2O of positive end-expiratory pressure (PEEP) to keep the alveoli from collapsing during exhalation.[9] Other treatments to improve oxygenation may include prone positioning or extracorporeal membrane oxygenation (ECMO).[6]

Prognosis[edit]

As expected, the mortality rates increase as the severity of the ARDS increases with mortality rates at approximately 35%, 40%, and 46% for mild, moderate, and severe, respectively.[11] It has been revealed that patients with ARDS that show DAD on histology are at a high mortality rate of 71.9% compared to 45.5% in patients with ARDS but without DAD.[12] Of the patients who succumb to ARDS, the most common cause of death is septic shock with multi organ dysfunction syndrome.[13]

Among survivors upon discharge, many will have impairments in their lung function. The majority (approximately 80%) of patient will have decrease diffusion capacity while fewer patients (approximately 20%) will have issues with airflow (either obstructive or restrictive).[14] These airflow issues will typically resolve within six months and the diffusion issues will resolve within five years.[14]

References[edit]

  1. ^ a b c d e f g Cardinal-Fernández, Pablo; Lorente, José A.; Ballén-Barragán, Aída; Matute-Bello, Gustavo (June 2017). "Acute Respiratory Distress Syndrome and Diffuse Alveolar Damage. New Insights on a Complex Relationship". Annals of the American Thoracic Society. 14 (6): 844–850. doi:10.1513/AnnalsATS.201609-728PS. ISSN 2329-6933. PMID 28570160.
  • ^ Berry, Gerald J; Rouse, Robert V (November 20, 2010). "Acute Interstitial Pneumonia - Diffuse Alveolar Damage". surgpathcriteria.stanford.edu. Archived from the original on 2014-11-23. Retrieved 2020-04-03.
  • ^ "Acute Respiratory Distress Syndrome (ARDS) | American Lung Association | American Lung Association". www.lung.org. Retrieved 2020-04-03.
  • ^ Siegel, Mark D (March 2020). "Acute Respiratory Distress Syndrome: Clinical Features, Diagnosis, and Complications in Adults". UpToDate. Archived from the original on 2020-04-11. Retrieved 2020-04-03.
  • ^ a b c Manicone, Anne M (2009-01-01). "Role of the pulmonary epithelium and inflammatory signals in acute lung injury". Expert Review of Clinical Immunology. 5 (1): 63–75. doi:10.1586/1744666X.5.1.63. ISSN 1744-666X. PMC 2745180. PMID 19885383.
  • ^ a b c Sweeney, Rob Mac; McAuley, Daniel F. (2016-11-12). "Acute respiratory distress syndrome". The Lancet. 388 (10058): 2416–2430. doi:10.1016/S0140-6736(16)00578-X. ISSN 0140-6736. PMC 7138018. PMID 27133972.
  • ^ Rezoagli, Emanuele; Fumagalli, Roberto; Bellani, Giacomo (July 2017). "Definition and epidemiology of acute respiratory distress syndrome". Annals of Translational Medicine. 5 (14): 282. doi:10.21037/atm.2017.06.62. ISSN 2305-5839. PMC 5537110. PMID 28828357.
  • ^ a b Agrawal, Rishi. "Respiratory distress syndrome | Radiology Reference Article | Radiopaedia.org". Radiopaedia. Retrieved 2020-04-09.
  • ^ a b Yoshikawa, A.; Fukuoka, J. "Acute respiratory distress syndrome (ARDS) / diffuse alveolar damage (DAD)". www.pathologyoutlines.com. Archived from the original on 2012-05-05. Retrieved 2020-04-09.
  • ^ Siegel, Mark D; Siemieniuk, Reed (March 25, 2020). "Acute Respiratory Distress Syndrome: Supportive Care and Oxygenation in Adults". UpToDate. Archived from the original on 2014-11-08. Retrieved April 9, 2020.
  • ^ Bellani, Giacomo; Laffey, John G.; Pham, Tài; Fan, Eddy; Brochard, Laurent; Esteban, Andres; Gattinoni, Luciano; van Haren, Frank; Larsson, Anders; McAuley, Daniel F.; Ranieri, Marco (2016-02-23). "Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries". JAMA. 315 (8): 788–800. doi:10.1001/jama.2016.0291. hdl:11573/859307. ISSN 1538-3598. PMID 26903337.
  • ^ Kao, Kuo-Chin; Hu, Han-Chung; Chang, Chih-Hao; Hung, Chen-Yiu; Chiu, Li-Chung; Li, Shih-Hong; Lin, Shih-Wei; Chuang, Li-Pang; Wang, Chih-Wei; Li, Li-Fu; Chen, Ning-Hung (2015-05-15). "Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy". Critical Care. 19 (1): 228. doi:10.1186/s13054-015-0949-y. ISSN 1466-609X. PMC 4449559. PMID 25981598.
  • ^ Stapleton, Renee D.; Wang, Bennet M.; Hudson, Leonard D.; Rubenfeld, Gordon D.; Caldwell, Ellen S.; Steinberg, Kenneth P. (August 2005). "Causes and timing of death in patients with ARDS". Chest. 128 (2): 525–532. doi:10.1378/chest.128.2.525. ISSN 0012-3692. PMID 16100134.
  • ^ a b Siegel, Mark D (March 2020). "Acute Respiratory Distress Syndrome: Prognosis and Outcomes in Adults". UpToDate. Archived from the original on 2020-07-30. Retrieved 2020-04-09.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Diffuse_alveolar_damage&oldid=1221861361"

    Category: 
    Histopathology
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
     



    This page was last edited on 2 May 2024, at 12:40 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki